The stock of Lipocine Inc (NASDAQ:LPCN) is a huge mover today! The stock decreased 6.59% or $0.24 on November 23, hitting $3.4. About 353,301 shares traded hands or 5.72% up from the average. Lipocine Inc (NASDAQ:LPCN) has declined 70.64% since April 22, 2016 and is downtrending. It has underperformed by 76.05% the S&P500.
The move comes after 9 months negative chart setup for the $58.85M company. It was reported on Nov, 24 by Barchart.com. We have $3.16 PT which if reached, will make NASDAQ:LPCN worth $4.12 million less.
Analysts await Lipocine Inc (NASDAQ:LPCN) to report earnings on March, 9. They expect $-0.33 EPS, down 32.00% or $0.08 from last year’s $-0.25 per share. After $-0.16 actual EPS reported by Lipocine Inc for the previous quarter, Wall Street now forecasts 106.25% negative EPS growth.
Lipocine Inc (NASDAQ:LPCN) Ratings Coverage
Out of 4 analysts covering Lipocine Inc (NASDAQ:LPCN), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Lipocine Inc has been the topic of 4 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, October 7 by H.C. Wainwright. The stock of Lipocine Inc (NASDAQ:LPCN) has “Buy” rating given on Wednesday, July 22 by TH Capital. On Wednesday, July 22 the stock rating was initiated by Roth Capital with “Buy”. The rating was maintained by Empire on Wednesday, August 12 with “Buy”.
According to Zacks Investment Research, “Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men’s and women’s health. The Company’s lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.”
More recent Lipocine Inc (NASDAQ:LPCN) news were published by: Marketwatch.com which released: “Lipocine Inc. NASDAQ: LPCN” on November 20, 2013. Also Law360.com published the news titled: “Lipocine Lied About Testosterone Pill’s Chances, Investors Say” on July 11, 2016. Seekingalpha.com‘s news article titled: “Lipocine Vs. Antares: Who Wins?” with publication date: April 20, 2016 was also an interesting one.
LPCN Company Profile
Lipocine Inc., incorporated on October 13, 2011, is a specialty pharmaceutical company. The Firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The Company’s primary development programs are based on oral delivery solutions for bioavailable drugs. The Firm has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. The Company’s lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.